ORTX(Delisted)
Orchard Therapeutics·NASDAQ
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ORTX
Orchard Therapeutics Plc
A global gene therapy leader
245 Hammersmith Road, London W6 8PW, United Kingdom
--
Orchard Therapeutics plc is a private limited liability company incorporated in England and Wales in August 2018. The company is a commercialized and fully integrated biopharmaceutical company dedicated to transforming serious life-threatening rare diseases through in vivo gene therapy. Their gene therapy approach aims to convert a patient's own or autologous HSC into a genetically modified drug product to treat the patient's disease with a single dose. They obtained this result by using a lentiviral vector to introduce a functional copy of the missing or defective gene into the patient's autologous HSC through an in vitro process, resulting in a drug product that can then be reintroduced into the patient at the bedside.
Company Financials
EPS
ORTX has released its 2023 Q3 earnings. EPS was reported at -0.15, versus the expected -0.75, beating expectations. The chart below visualizes how ORTX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ORTX has released its 2023 Q3 earnings report, with revenue of 6.30M, reflecting a YoY change of 9.09%, and net profit of -35.32M, showing a YoY change of 25.75%. The Sankey diagram below clearly presents ORTX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
